Breaking down the barriers to drug development
9 Jan 2015
Dr. Francoise Meunier, EORTC Director General, Sir Michael Rawlins, former chair of NICE, and Robert Strieter, Novartis Institutes for Biomedical Research discuss translational medicine in respiratory disease in Prof. Peter Barnes’ latest instalment of ERS Vision. The film looks at ways to break down the barriers that obstruct and delay the development of new medicines at every stage of the discovery process.
Leading experts in the field tackle issues such as data protection, risk management, protocol development and European regulations, and emphasise the importance of developing active collaborations between the different stakeholders involved in the drug development process.
Related News
Professor Benjamin Besse becomes President of EORTC
26 Jun 2026
CCTG, EORTC and UK3CR welcome G7 commitment to accelerate global progress against cancer
24 Jun 2026
EORTC welcomes EU Biotech Act and calls for refinements to enable patient-centred trials
24 Jun 2026
New study confirms a key quality of life tool can be used with adolescents with cancer
9 Jun 2026
“Changing practice, improving lives”: EORTC publishes its Annual Report 2025
8 Jun 2026
This Clinical Trials Day, EORTC announces the upcoming Summit for Clinical Cancer Research
20 May 2026
Long-term EORTC trial challenges assumptions about lymph node radiation therapy in breast cancer
17 May 2026
Multinational study provides new evidence for the value of response-adapted, personalised treatment in Hodgkin lymphoma
1 May 2026
EORTC’s presence at ESTRO 2026
30 Apr 2026
Independent, academic cancer trials are vital to improve patient outcomes worldwide
28 Apr 2026
